Trametinib, an orally administered commercially available MEK inhibitor (MEKi), is currently being investigated in the treatment of surgically inoperable tumors associated with neurofibromatosis type 1 (NF1).1,2 A potential benefit of trametinib for plexiform neurofibromas is suggested by the effectiveness of the MEKi selumetinib in previous studies.3 Trametinib and selumetinib both have the potential to cause cutaneous toxic reactions, most frequently folliculitis eruptions, that can require dosage modifications or drug discontinuation.4,5 These rashes are treated with a variety of therapies with differing rates of success.4 In this case report, we describe a series of 5 patients with NF1 and surgically inoperable plexiform neurofibromas being treated with trametinib. These patients developed folliculitis eruptions and were treated with oral fluconazole after biopsies in 2 patients showed evidence of fungal involvement.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Steele C, Gershon T, Burkhart C, Googe P. Treatment of Trametinib-Associated Folliculitis Eruption With Fluconazole. JAMA Dermatol. 2020;156(6):706–708. doi:10.1001/jamadermatol.2020.0284
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: